|
128 Companies |
|
121 Products |
|
121 Products |
|
104 Mechanisms of Action |
|
7 Trials |
|
1812 News |
|
| «12...25262728293031323334353637» |
- |||| trebananib (AMG 386) / Amgen
Trial completion, Combination therapy, Metastases: Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma (clinicaltrials.gov) - Dec 11, 2012
P2, N=171, Completed, Sponsor: Amgen
Active, not recruiting --> Completed
- ||| Trial completion: Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury (clinicaltrials.gov) - Dec 6, 2012
P=N/A, N=100, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Recruiting --> Completed
- | armodafinil / Generic mfg.
New P2 trial, P2 data: A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer (clinicaltrials.gov) - Dec 6, 2012
P2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Clinical: Minimal Change Esophagitis by i-Scan Endoscopy in Dyspeptic Patients (clinicaltrials.gov) - Dec 3, 2012
P=N/A, N=200, Enrolling by invitation, Sponsor: Prince of Songkla University
- Biomarker: Laparoscopic Total Fundoplication for Duodenogastroesophageal Reflux (clinicaltrials.gov) - Dec 3, 2012
P=N/A, N=188, Completed, Sponsor: University of Turin, Italy
- Clinical: Oeso-Chemo: Effects of Chemotherapy on Muscle Mass and Exercise Performance in Patients With Oesophageal Cancer. (clinicaltrials.gov) - Dec 3, 2012
P=N/A, N=25, Recruiting, Sponsor: University of Nottingham
- || New P3 trial: ESOPRESSO: Role of Esophagectomy in Complete Responders to CCRT (clinicaltrials.gov) - Dec 2, 2012
P3, N=486, Recruiting, Sponsor: Asan Medical Center
- Enrollment open: Tongue Pressure Profile Training for Dysphagia Post Stroke (clinicaltrials.gov) - Nov 29, 2012
P2, N=60, Recruiting, Sponsor: Toronto Rehabilitation Institute
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Fecal Screening Assay for Taiwanese Population (clinicaltrials.gov) - Nov 29, 2012
P=N/A, N=3172, Completed, Sponsor: National Taiwan University Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing (clinicaltrials.gov) - Nov 29, 2012
P4, N=200, Completed, Sponsor: National Taiwan University Hospital
Recruiting --> Completed Recruiting --> Completed
- HEOR: Quality of Life After Esophagectomy for Cancer - Step 2 (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=128, Recruiting, Sponsor: University of Padova
- HEOR: Quality of Life After Esophagectomy for Cancer - Step 1 (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=128, Recruiting, Sponsor: University of Padova
- Trial completion: A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis (clinicaltrials.gov) - Nov 28, 2012
P1, N=20, Completed, Sponsor: Penn State University
Recruiting --> Completed Recruiting --> Completed
- | gefitinib / Generic mfg.
Trial completion: Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy (clinicaltrials.gov) - Nov 27, 2012
P3, N=450, Completed, Sponsor: University of Oxford
Recruiting --> Completed Recruiting --> Completed
- davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial initiation date, Surgery, Metastases: Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery (clinicaltrials.gov) - Nov 20, 2012
P=N/A, N=11, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Completed Initiation date: Jul 2012 --> Nov 2012
- davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment open, Surgery, Metastases: Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery (clinicaltrials.gov) - Nov 20, 2012
P=N/A, N=11, Recruiting, Sponsor: City of Hope Medical Center
Initiation date: Jul 2012 --> Nov 2012 Not yet recruiting --> Recruiting
- omeprazole / Generic mfg.
Trial completion: A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication Treatment of Patients With Chronic GERD (clinicaltrials.gov) - Nov 13, 2012
P=N/A, N=216, Completed, Sponsor: McMaster University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial termination, Surgery, Metastases: Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers (clinicaltrials.gov) - Nov 8, 2012
P2, N=8, Terminated, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Due to slow accrual
- oxaliplatin / Generic mfg., cisplatin / Generic mfg., sorafenib / Generic mfg.
Trial completion, Metastases: Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment (clinicaltrials.gov) - Nov 7, 2012
P2, N=41, Completed, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Active, not recruiting --> Terminated; Due to slow accrual Recruiting --> Completed
- | Takecab (vonoprazan) / Takeda, Phathom Pharma
Trial completion: Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis (clinicaltrials.gov) - Nov 6, 2012
P3, N=409, Completed, Sponsor: Takeda Pharmaceutical Company Limited
Recruiting --> Completed Recruiting --> Completed
- ||||| Biomarker, Enrollment closed: BIOBAR: Biomarkers in Phototherapy of Barrett's Esophagus (clinicaltrials.gov) - Nov 5, 2012
P2/3, N=208, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed Recruiting --> Active, not recruiting
- New P2 trial: Neuromuscular Electrical Stimulation (NMES) Treatment Technique Therapy in the Management of Young Infants With Severe Dysphagia (clinicaltrials.gov) - Nov 5, 2012
P2, N=10, Active, not recruiting, Sponsor: The Hospital for Sick Children
- Acetavance (acetaminophen) / Mallinckrodt
New P4 trial: Acetaminophen's Efficacy For Post-operative Pain (clinicaltrials.gov) - Nov 1, 2012
P4, N=40, Recruiting, Sponsor: Kaveh Aslani, MD
- escitalopram / Generic mfg.
Trial termination, Metastases: Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer (clinicaltrials.gov) - Nov 1, 2012
P3, N=24, Terminated, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; DSMB stopped study because placebo arm had more adverse events
- escitalopram / Generic mfg.
Enrollment change, Metastases: Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer (clinicaltrials.gov) - Nov 1, 2012
P3, N=24, Terminated, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Terminated; DSMB stopped study because placebo arm had more adverse events N=220 --> 24
- | fluticasone propionate ODT (APT-1011) / Ellodi Pharma
Enrollment open: A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021 (clinicaltrials.gov) - Oct 30, 2012
P1/2, N=24, Enrolling by invitation, Sponsor: Aptalis Pharma
N=220 --> 24 Not yet recruiting --> Enrolling by invitation
- | fluticasone propionate ODT (APT-1011) / Ellodi Pharma
Trial completion: Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis (clinicaltrials.gov) - Oct 30, 2012
P1/2, N=24, Completed, Sponsor: Aptalis Pharma
Not yet recruiting --> Enrolling by invitation Recruiting --> Completed
- indomethacin / Generic mfg.
New P1 trial, Combination therapy: PIFA: Phase I Platinum Based Chemotherapy Plus Indomethacin (clinicaltrials.gov) - Oct 30, 2012
P1, N=18, Recruiting, Sponsor: UMC Utrecht
- gefitinib / Generic mfg.
Trial completion, Metastases: Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Oct 29, 2012
P2, N=58, Completed, Sponsor: David Adelstein
Recruiting --> Completed Active, not recruiting --> Completed
- Trial withdrawal: A Study to Evaluate the Role of Alternative Medicine in Difficult to Treat GERD Patients (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=0, Withdrawn, Sponsor: Midwest Biomedical Research Foundation
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: A Study to Evaluate the Role of Alternative Medicine in Difficult to Treat GERD Patients (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=0, Withdrawn, Sponsor: Midwest Biomedical Research Foundation
Not yet recruiting --> Withdrawn N=45 --> 0
- Enrollment change: Narrow Band Imaging Project on Barrett's Esophagus (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=50, Not yet recruiting, Sponsor: Midwest Biomedical Research Foundation
N=45 --> 0 N=200 --> 50
- | 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Biomarker, New P2 trial, Metastases: Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. (clinicaltrials.gov) - Oct 24, 2012
P2, N=127, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- | Enrollment closed: Open Versus Laparoscopically-assisted Esophagectomy for Cancer (clinicaltrials.gov) - Oct 21, 2012
P3, N=200, Active, not recruiting, Sponsor: University Hospital, Lille
N=200 --> 50 Recruiting --> Active, not recruiting
- |||||||||| New P3 trial: Clinical Study, Multicenter, Randomized With 2 Arms of Pantoprazole + Domperidone and Pantoprazole Isolated at the Gastroesophageal Reflux Disease (clinicaltrials.gov) - Oct 17, 2012
P3, N=292, Not yet recruiting, Sponsor: Eurofarma Laboratorios S.A.
- New P2 trial, Metastases: A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer (clinicaltrials.gov) - Oct 17, 2012
P2, N=35, Completed, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
- | New P1 trial: A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions (clinicaltrials.gov) - Oct 17, 2012
P1, N=20, Completed, Sponsor: Norgine
- Trial completion: A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders (clinicaltrials.gov) - Oct 16, 2012
P3, N=30, Completed, Sponsor: Marc Rothenberg
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | ONO-8539 / Ono Pharma
New P1 trial: A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease (clinicaltrials.gov) - Oct 14, 2012
P1, N=30, Recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
- | ONO-8539 / Ono Pharma
New P1 trial: A Study to Investigate the Effect of ONO-8539 on Acid-Induced Oesophageal Hypersensitivity in Healthy Volunteers (clinicaltrials.gov) - Oct 10, 2012
P1, N=20, Active, not recruiting, Sponsor: Ono Pharmaceutical Co. Ltd
- MK-2206 / Merck (MSD), Herceptin (trastuzumab) / Roche
New P1 trial, Combination therapy, Surgery, Metastases: Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Oct 10, 2012
P1, N=60, Terminated, Sponsor: National Cancer Institute (NCI)
- lansoprazole / Generic mfg.
Biomarker, Trial withdrawal: Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children (clinicaltrials.gov) - Oct 9, 2012
P4, N=0, Withdrawn, Sponsor: Osaka University
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- | AZD1386 / AstraZeneca
Enrollment change: Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD) (clinicaltrials.gov) - Oct 9, 2012
P2a, N=14, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Withdrawn N=30 --> 14
- omeprazole / Generic mfg.
Trial completion: OMEPRAZOLE-1: Optimal Dosing of Omeprazole in Neonates (clinicaltrials.gov) - Oct 9, 2012
P2, N=55, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=30 --> 14 Terminated --> Completed
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment open, Metastases: Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer (clinicaltrials.gov) - Oct 9, 2012
P2/3, N=80, Recruiting, Sponsor: Peking University
Terminated --> Completed Not yet recruiting --> Recruiting
- lapatinib / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment open, Metastases: Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 9, 2012
P1, N=15, Recruiting, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | sorafenib / Generic mfg.
Enrollment closed, Metastases: Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer (clinicaltrials.gov) - Oct 9, 2012
P2, N=35, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: Esophageal Protocol for Detection of Neoplasia in the Digestive Tract (clinicaltrials.gov) - Oct 9, 2012
P1, N=25, Completed, Sponsor: University of Michigan
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Trial completion: Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE) (clinicaltrials.gov) - Oct 3, 2012
P=N/A, N=25, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed Active, not recruiting --> Completed
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2/3 trial, Metastases: Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer (clinicaltrials.gov) - Oct 3, 2012
P2/3, N=80, Recruiting, Sponsor: Peking University